Non-Cystic Fibrosis Bronchiectasis Pipeline Set for Significant Expansion by 2026 with 12+ Therapies and Robust Clinical Progress from Haisco Pharmaceutical, CSL Behring, Insmed, Zambon | DelveInsight

Non-Cystic Fibrosis Bronchiectasis Clinical Trials

The Non-Cystic Fibrosis Bronchiectasis (NCFB) therapeutic landscape is witnessing a strong wave of innovation, driven by increasing disease burden, advancements in respiratory drug development, and a growing focus on targeted anti-inflammatory and anti-infective therapies. Leading companies such as Haisco Pharmaceutical Group, CSL Behring, Insmed Incorporated, Zambon SpA, Armata Pharmaceuticals, NovaBiotics, and Chiesi Farmaceutici are actively reshaping the future of bronchiectasis treatment through a dynamic and evolving pipeline.

DelveInsight’s latest report, “Non-Cystic Fibrosis Bronchiectasis Pipeline Insight, 2026,” provides comprehensive insights into 10+ companies and 12+ pipeline therapies in this space. The report offers a detailed evaluation of pipeline drug profiles, spanning clinical and nonclinical stages, along with a thorough therapeutic assessment based on product type, stage of development, route of administration, and molecule type. It also highlights inactive and discontinued pipeline assets, offering a complete view of the evolving competitive landscape.

Unlock in-depth pipeline intelligence and strategic insights here:Non-Cystic Fibrosis Bronchiectasis Clinical Trial Analysis

Key Takeaways from the Non-Cystic Fibrosis Bronchiectasis Pipeline Report

• The NCFB pipeline includes 12+ active therapeutic candidates across early, mid, and late stages of development.
• Increasing focus on anti-inflammatory and anti-infective mechanisms is transforming treatment approaches.
• Novel targets such as DPP1 inhibition and immunoglobulin-based therapies are gaining significant traction.
• Strategic collaborations and licensing agreements are accelerating clinical development timelines.
• The shift toward inhalation-based drug delivery systems is improving therapeutic precision and patient compliance.
• Personalized treatment strategies are emerging as a key trend in bronchiectasis management.
• Growing clinical trial activity reflects heightened industry interest and investment in this therapeutic area.
• In April 2026, Sanofi announced results of a Randomized, Double-blinded, Placebo-controlled, Parallel Group, Phase 2a Study to Assess the Activity, Safety, and Tolerability of SAR445399 in Adult Participants With Non-Cystic Fibrosis Bronchiectasis (NCFB)
• In April 2026, Physio-Assist announced evaluation of the Impact of SIMEOX Airway Clearance Medical Device at Home, Combined With Remote Physiotherapy, on Quality of Life and Pulmonary Exacerbations in Patients With Non-cystic Fibrosis Bronchiectasis, Compared With Enhanced Standard of Care
• In November 2025, Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that the European Commission has approved BRINSUPRI (brensocatib 25 mg tablets) for the treatment of non-cystic fibrosis bronchiectasis (NCFB) in patients 12 years of age and older with two or more exacerbations in the prior 12 months. BRINSUPRI is a first-in-class therapy, offering the first and only approved treatment indicated for NCFB in the European Union (EU). BRINSUPRI was reviewed under accelerated assessment by the EMA as it is deemed to be of major interest for public health.
• In August 2025, the FDA approved Insmed’s BRINSUPRI (brensocatib), the first oral therapy for non-cystic fibrosis bronchiectasis (NCFB) in patients 12 years and older. Insmed has set the annual price at $88,000 before discounts.
• In February 2025, Insmed Incorporated announced that the FDA has accepted its New Drug Application (NDA) for brensocatib, intended for patients with non-cystic fibrosis bronchiectasis. The FDA granted Priority Review and set a target action date of August 12, 2025, under the Prescription Drug User Fee Act (PDUFA).
• In October 2024, Insmed shared positive late-breaking subgroup data from the Phase III ASPEN study of brensocatib for patients with NCFB at the CHEST 2024 Annual Meeting.

Understanding Non-Cystic Fibrosis Bronchiectasis: A Chronic and Progressive Pulmonary Disorder

Non-Cystic Fibrosis Bronchiectasis is a chronic and progressive respiratory condition characterized by irreversible dilation of the bronchi, impaired mucociliary clearance, and persistent inflammation of the airways. Patients suffering from this condition commonly experience chronic productive cough, daily sputum production, breathlessness, and frequent exacerbations driven by recurrent infections.

The disease significantly impacts patients’ quality of life and imposes a substantial healthcare burden due to repeated hospitalizations and long-term treatment requirements. One of the most critical aspects of managing bronchiectasis lies in identifying and addressing the underlying causes, which may include severe infections, immune deficiencies, aspiration, or environmental exposures.

A widely accepted mechanism underlying disease progression is Cole’s “vicious cycle,” which involves a continuous loop of infection, inflammation, and structural lung damage. This cycle is initiated when the lung’s defense mechanisms are compromised, leading to impaired mucociliary clearance and mucus accumulation in the airways. The retained mucus creates an environment conducive to microbial colonization, further triggering chronic inflammation.

Pathogens such as Pseudomonas aeruginosa play a particularly important role in disease progression by forming biofilms that protect bacteria from immune responses and antibiotic treatment. These biofilms contribute to persistent infections and exacerbate airway damage, reinforcing the cycle of disease progression.

Despite advancements in respiratory medicine, a significant proportion of bronchiectasis cases—estimated at 30% to 50%—remain idiopathic, underscoring the urgent need for innovative therapies that can effectively target underlying mechanisms rather than merely alleviating symptoms.

Evolving NCFB Pipeline Landscape: Innovation Driving Therapeutic Transformation

The Non-Cystic Fibrosis Bronchiectasis pipeline is undergoing a paradigm shift, fueled by breakthroughs in immunology, microbiology, and targeted drug development. Pharmaceutical and biotechnology companies are increasingly focusing on therapies that disrupt the underlying disease mechanisms, including neutrophilic inflammation, chronic infection, and mucus hypersecretion.

Request a detailed sample report to explore emerging therapies and clinical advancements:Non-Cystic Fibrosis Bronchiectasis Competitive Landscape

According to DelveInsight, approximately 10+ key companies are actively engaged in developing therapies for NCFB, with a combined pipeline of 12+ drug candidates across various stages of development. These therapies aim to address critical unmet needs such as reducing exacerbation frequency, improving lung function, and enhancing long-term disease management.

The pipeline reflects a growing emphasis on:

• Targeting neutrophil-driven inflammation
• Combating chronic bacterial infections
• Enhancing mucociliary clearance
• Developing inhaled and localized therapies to improve efficacy and reduce systemic side effects

Non-Cystic Fibrosis Bronchiectasis Emerging Drugs Profile

HSK31858: Haisco Pharmaceutical Group Co., Ltd.

HSK31858 is a highly selective oral dipeptidyl peptidase 1 (DPP1) inhibitor designed to target neutrophil-driven inflammation, a key contributor to bronchiectasis progression. By inhibiting DPP1, the drug prevents the activation of neutrophil serine proteases, thereby reducing inflammation and tissue damage.

The therapy has successfully completed Phase I and II clinical trials and is currently advancing through Phase III clinical development, positioning it as one of the most promising late-stage candidates in the NCFB pipeline. Its targeted mechanism and oral administration offer significant advantages in terms of patient convenience and therapeutic efficacy.

CSL 787: CSL Behring

CSL 787 is an innovative nebulized human plasma-derived immunoglobulin therapy aimed at preventing chronic respiratory infections and slowing disease progression. By enhancing local immune defense within the lungs, the therapy seeks to reduce infection frequency and improve clinical outcomes.

Currently in Phase II clinical trials, CSL 787 represents a novel approach to managing bronchiectasis by addressing immune dysfunction, a critical yet often overlooked component of the disease.

Additional Emerging Non-Cystic Fibrosis Bronchiectasis Therapies

The pipeline also includes several other promising candidates such as:

• Brensocatib (Insmed Incorporated) – a DPP1 inhibitor targeting neutrophilic inflammation
• CHF 6333 (Chiesi Farmaceutici) – an inhaled anti-inflammatory therapy
• AP-PA02 (Armata Pharmaceuticals) – a bacteriophage-based therapy targeting resistant bacterial infections
• ARINA-1 (Insmed/Zambon) – an inhaled multi-mechanistic formulation
• Colistimethate sodium (Zambon SpA) – an inhaled antibiotic for chronic infections

Explore comprehensive drug profiles and clinical insights:Non-Cystic Fibrosis Bronchiectasis Pipeline Outlook

Non-Cystic Fibrosis Bronchiectasis Pipeline Segmentation and Therapeutic Assessment

The report provides a detailed segmentation of NCFB pipeline therapies across multiple parameters:

Non-Cystic Fibrosis Bronchiectasis Clinical Development Phases

• Late-stage (Phase III)
• Mid-stage (Phase II)
• Early-stage (Phase I)
• Preclinical and discovery-stage candidates
• Inactive and discontinued programs

Non-Cystic Fibrosis Bronchiectasis Route of Administration

• Oral
• Intravenous
• Subcutaneous
• Intramuscular
• Inhalation-based therapies

Non-Cystic Fibrosis Bronchiectasis Molecule Types

• Small molecules
• Monoclonal antibodies
• Peptides
• Immunoglobulin-based therapies

Non-Cystic Fibrosis Bronchiectasis Product Types

• Monotherapy
• Combination therapy
• Mono/Combination approaches

This diverse therapeutic landscape highlights the complexity of bronchiectasis and the need for multifaceted treatment strategies.

Non-Cystic Fibrosis Bronchiectasis Clinical Trial Activity and Strategic Collaborations

The Non-Cystic Fibrosis Bronchiectasis pipeline is marked by increasing clinical trial activity across global markets. Companies are actively pursuing partnerships, licensing deals, and acquisitions to strengthen their R&D capabilities and accelerate drug development.

Key players such as Haisco Pharmaceutical Group, CSL Behring, Insmed Incorporated, and Zambon SpA are leading innovation through targeted therapies and advanced clinical programs. Meanwhile, emerging biotech firms are exploring disruptive approaches such as bacteriophage therapy and inhaled immunotherapies.

Stay ahead with the latest clinical trial updates and partnership insights:Non-Cystic Fibrosis Bronchiectasis Clinical Trial and FDA Approvals

Non-Cystic Fibrosis Bronchiectasis Market Drivers, Challenges, and Future Outlook

Key Non-Cystic Fibrosis Bronchiectasis Market Growth Drivers

• Rising prevalence of chronic respiratory diseases
• Increasing awareness and improved diagnostic capabilities
• Growing demand for targeted and personalized therapies
• Advancements in inhalation drug delivery technologies
• Expanding research into microbiome and immune modulation

Non-Cystic Fibrosis Bronchiectasis Market Challenges

• Heterogeneous disease etiology
• Lack of standardized treatment guidelines
• Limited availability of disease-modifying therapies
• Challenges in clinical trial design and patient recruitment

Despite these challenges, the future of the NCFB pipeline looks promising. The integration of precision medicine, biomarker-driven approaches, and advanced drug delivery systems is expected to significantly enhance treatment outcomes.

As multiple late-stage candidates approach commercialization, the bronchiectasis treatment landscape is poised for a transformative shift, offering new hope to patients and healthcare providers alike.

Download free sample report now:Non-Cystic Fibrosis Bronchiectasis Drugs and Therapies

Scope of the Non-Cystic Fibrosis Bronchiectasis Pipeline Report

• Coverage: Global
• Key NCFB Companies: Zambon SpA, Insmed Incorporated, NovaBiotics, Haisco Pharmaceutical Group, Armata Pharmaceuticals, Chiesi Farmaceutici, CSL Behring, and others
• Key NCFB ATherapies: HSK31858, CSL 787, Brensocatib, CHF 6333, AP-PA02, ARINA-1, Colistimethate sodium
• Therapeutic Assessment: By product type, clinical stage, route of administration, and molecule type

Key Questions Answered

• How many companies are actively developing NCFB therapies?
• What is the distribution of drugs across different clinical stages?
• What novel mechanisms and technologies are emerging in this space?
• What are the key collaborations and licensing deals shaping the market?
• What unmet needs remain in bronchiectasis treatment?
• Which therapies are expected to drive future market growth?

Table of Contents

1. Introduction
2. Executive Summary
3. Disease Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Analytical Perspective
7. Late-Stage Products
8. Mid-Stage Products
9. Early-Stage Products
10. Inactive Products
11. Key Companies
12. Key Products
13. Unmet Needs
14. Market Drivers and Barriers
15. Future Perspectives

About DelveInsight

DelveInsight is a leading business consulting and market research firm specializing in life sciences. The company provides actionable insights to support strategic decision-making across pharmaceutical, biotechnology, and medical device industries.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting